-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
December 1, pharmaceutical outsourcing company Medicilon public disclosure record sheet investor relations activities, the company on November 30, 2021 to accept 238 research establishments, type of institution, including QFII, insurance companies, other fund companies
.
From the question and answer session, the organization mainly focuses on the current order status and expectations of Medicilon, the main reasons for business growth, the planning status in CDMO, and the views on the future development of the industry
.
The third quarter report of 2021 shows that from January to September 2021, Medicilon achieved operating income of 786 million, an increase of 81.
62% year-on-year; net profit attributable to shareholders of listed companies and net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses Net profits were 181 million yuan and 176 million yuan, respectively, with year-on-year growth of 142.
06% and 145.
70%
.
Regarding the current order situation and business growth reasons, Medicilon said that the company’s new orders are currently in good condition, and the company’s business development work is actively advancing
.
The steady growth of the company's performance is mainly due to the continuous growth of domestic and foreign drug research and development.
The company's management team insists on simultaneously improving research and development service capabilities and market expansion capabilities
.
In terms of CDMO, Medicilon said that pharmaceutical research services include API research services and preparation research services, and are still in the laboratory research stage
.
CDMO/CMO is the direction of the company's future efforts to focus on expansion
.
The company plans to expand the CDMO service level and establish a large-scale production base that meets GMP standards through its own construction or mergers and acquisitions
.
The future development of the CRO industry has attracted the attention of institutions.
Medicilon pointed out that China’s CRO industry is an emerging industry that has only developed in the past two decades.
At present, the domestic CRO industry as a whole shows a pattern of multiple, small, and scattered, and the industry concentration is relatively Lower
.
Under the background of domestic pharmaceutical policies that encourage the development of generic drugs to innovative drugs, and the domestic regulatory level is in line with international standards, attracting the transfer of international pharmaceutical research and development needs, the domestic CRO market has rapidly expanded.
.
In addition, China's pharmaceutical industry is in a golden period of development towards independent innovation.
The investment in pharmaceutical research and development continues to increase.
In the future, as the domestic demand for innovative drug research and development accelerates, the CRO industry will usher in a golden opportunity for industry development that continues to grow
.
It is worth mentioning that the CRO industry is a talent-intensive industry.
In order to meet the growing business needs, Medicilon said that it has also deployed professional and technical personnel.
In the first three quarters of 2021, the number of personnel in the company's three business sectors has grown rapidly
.
At the same time, it is stated that the company's personnel recruitment plan will be matched with the company's business growth and development and be reasonably configured to ensure future business development and project implementation
.
Regarding the direction of the company's guarantee of performance growth in the next few years, Medicilon revealed that it will continue to focus on preclinical research services for a period of time in the future, through the drug discovery and pharmaceutical research and reporting platform of the Center for Innovative Drug Research and International Filing, and innovative drug research The construction and implementation of the pre-clinical research and reporting platform of the International Reporting Center will continue to strengthen the company's professional service capabilities in the fields of chemistry, biology, APIs, preparations and preclinical research
.
In addition, in the next three to five years, the rapid development of its own scale and complementary mergers and acquisitions, especially in the integrated research services of drug CDMO/CMO and biopharmaceuticals, are also the focus of the company's efforts to expand
.
Public information shows that Medicilon is a professional biomedicine preclinical comprehensive research and development service CRO, providing a full range of one-stop new drug research and development services that meet domestic and international reporting standards for global pharmaceutical companies and scientific research institutions
.
The company's services cover the entire process of pre-clinical new drug research, including drug discovery, pharmaceutical research and pre-clinical research
.
.
From the question and answer session, the organization mainly focuses on the current order status and expectations of Medicilon, the main reasons for business growth, the planning status in CDMO, and the views on the future development of the industry
.
The third quarter report of 2021 shows that from January to September 2021, Medicilon achieved operating income of 786 million, an increase of 81.
62% year-on-year; net profit attributable to shareholders of listed companies and net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses Net profits were 181 million yuan and 176 million yuan, respectively, with year-on-year growth of 142.
06% and 145.
70%
.
Regarding the current order situation and business growth reasons, Medicilon said that the company’s new orders are currently in good condition, and the company’s business development work is actively advancing
.
The steady growth of the company's performance is mainly due to the continuous growth of domestic and foreign drug research and development.
The company's management team insists on simultaneously improving research and development service capabilities and market expansion capabilities
.
In terms of CDMO, Medicilon said that pharmaceutical research services include API research services and preparation research services, and are still in the laboratory research stage
.
CDMO/CMO is the direction of the company's future efforts to focus on expansion
.
The company plans to expand the CDMO service level and establish a large-scale production base that meets GMP standards through its own construction or mergers and acquisitions
.
The future development of the CRO industry has attracted the attention of institutions.
Medicilon pointed out that China’s CRO industry is an emerging industry that has only developed in the past two decades.
At present, the domestic CRO industry as a whole shows a pattern of multiple, small, and scattered, and the industry concentration is relatively Lower
.
Under the background of domestic pharmaceutical policies that encourage the development of generic drugs to innovative drugs, and the domestic regulatory level is in line with international standards, attracting the transfer of international pharmaceutical research and development needs, the domestic CRO market has rapidly expanded.
.
In addition, China's pharmaceutical industry is in a golden period of development towards independent innovation.
The investment in pharmaceutical research and development continues to increase.
In the future, as the domestic demand for innovative drug research and development accelerates, the CRO industry will usher in a golden opportunity for industry development that continues to grow
.
It is worth mentioning that the CRO industry is a talent-intensive industry.
In order to meet the growing business needs, Medicilon said that it has also deployed professional and technical personnel.
In the first three quarters of 2021, the number of personnel in the company's three business sectors has grown rapidly
.
At the same time, it is stated that the company's personnel recruitment plan will be matched with the company's business growth and development and be reasonably configured to ensure future business development and project implementation
.
Regarding the direction of the company's guarantee of performance growth in the next few years, Medicilon revealed that it will continue to focus on preclinical research services for a period of time in the future, through the drug discovery and pharmaceutical research and reporting platform of the Center for Innovative Drug Research and International Filing, and innovative drug research The construction and implementation of the pre-clinical research and reporting platform of the International Reporting Center will continue to strengthen the company's professional service capabilities in the fields of chemistry, biology, APIs, preparations and preclinical research
.
In addition, in the next three to five years, the rapid development of its own scale and complementary mergers and acquisitions, especially in the integrated research services of drug CDMO/CMO and biopharmaceuticals, are also the focus of the company's efforts to expand
.
Public information shows that Medicilon is a professional biomedicine preclinical comprehensive research and development service CRO, providing a full range of one-stop new drug research and development services that meet domestic and international reporting standards for global pharmaceutical companies and scientific research institutions
.
The company's services cover the entire process of pre-clinical new drug research, including drug discovery, pharmaceutical research and pre-clinical research
.
